9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER

Pier Franco Conte, Giancarlo Bisagni, Antonio Frassoldati, Alba Ariela Brandes, Elisa Anselmi, Francesco Giotta, Michele Aieta, Vittorio Gebbia, Antonino Musolino, Ornella Garrone, Cristiana Taverniti, Giovanna Cavazzini, Anna Turletti, Daniela Rubino, Elisa Picardo, Antonella Ferro, Federico Piacentini, Sara Balduzzi, Roberto D‘Amico, Valentina Guarneri

Department of Surgery, Oncology and Gastroenterology, University of Padua, Medical Oncology 2, Instituto Oncologico Veneto IRCCS, Padova, Italy
Medical Oncology Unit, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Division of Oncology, Ferrara University Hospital, Ferrara, Italy
Medical Oncology Department, Bellaria Hospital, AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy
Department of Onco-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
National Cancer Research Centre Giovanni Paolo II, Bari, Italy
Department of Onco-Hematology, Division of Medical Oncology, Centro di Riferimento Oncologico della Basilicata IRCCS, Rionero, Italy
Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy
Medical Oncology Unit, University Hospital of Parma, Parma, Italy
Medical Oncology, S. Croce and Carle Teaching Hospital, Cuneo, Italy
Medical Oncology, AOU Cittá della Salute e della Scienza, Torino, Italy
Medical Oncology, Azienda Ospedaliera Carlo Poma, Mantova, Italy
Medical Oncology, ASLTO1 Ospedale Martini, Torino, Italy
Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy
University Department of Gynecology and Obstetrics, S.Anna Hospital, Torino, Italy
Medical Oncology, Santa Chiara Hospital, Trento, Italy
Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, Modena, Italy
Department of Diagnostic Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy